Pfizer Future Growth

Future criteria checks 3/6

Pfizer is forecast to grow earnings and revenue by 29.7% and 2.6% per annum respectively. EPS is expected to grow by 29.5% per annum. Return on equity is forecast to be 15.3% in 3 years.

Key information

29.7%

Earnings growth rate

29.5%

EPS growth rate

Pharmaceuticals earnings growth	23.5%
Revenue growth rate	2.6%
Future return on equity	15.3%
Analyst coverage	Good
Last updated	07 May 2024

Recent future growth updates

Recent updates

Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns

Mar 18

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Mar 08

Pfizer: A Value Trap, Not A Bargain

Feb 28

Pfizer: Turnaround Is Gaining Momentum

Feb 21

Is Pfizer (NYSE:PFE) A Risky Investment?

Feb 21

Pfizer Is A Great Investment Over The Next Decade; Buy

Feb 09

Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market

Jan 31

Why I'm Avoiding 6%-Yielding Pfizer Stock

Jan 23

Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort

Jan 12

Earnings and Revenue Growth Forecasts

NYSE:PFE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	63,142	11,505	16,181	N/A	20
12/31/2025	62,546	11,139	14,672	N/A	22
12/31/2024	60,232	7,184	9,957	N/A	22
3/31/2024	54,889	-288	N/A	N/A	N/A
12/31/2023	58,496	2,134	4,793	8,700	N/A
10/1/2023	68,537	10,469	8,178	12,042	N/A
7/2/2023	77,943	21,494	10,665	14,560	N/A
4/2/2023	92,951	29,035	20,206	23,938	N/A
12/31/2022	100,330	31,366	26,031	29,267	N/A
10/2/2022	99,878	29,953	23,362	26,599	N/A
7/3/2022	101,275	29,481	28,440	31,454	N/A
4/3/2022	92,433	25,410	31,783	34,583	N/A
12/31/2021	81,288	22,413	29,869	32,580	N/A
10/3/2021	68,877	19,485	29,769	32,291	N/A
7/4/2021	55,119	12,236	21,141	23,552	N/A
4/4/2021	46,084	9,032	13,477	15,808	N/A
12/31/2020	41,651	6,630	12,177	14,403	N/A
9/27/2020	32,334	212	10,512	12,547	N/A
6/28/2020	34,737	6,977	12,777	14,967	N/A
3/29/2020	38,137	9,427	11,702	14,023	N/A
12/31/2019	40,905	10,707	10,542	12,588	N/A
9/29/2019	53,039	16,211	10,897	13,557	N/A
6/30/2019	53,656	12,638	11,746	14,306	N/A
3/31/2019	53,859	11,464	13,146	15,542	N/A
12/31/2018	40,825	3,824	13,691	15,827	N/A
9/30/2018	53,373	23,808	16,001	18,178	N/A
7/1/2018	53,244	22,545	15,596	17,808	N/A
4/1/2018	52,673	21,746	14,924	17,201	N/A
12/31/2017	52,546	21,305	N/A	16,802	N/A
10/1/2017	52,471	9,791	N/A	15,463	N/A
7/2/2017	52,347	8,308	N/A	15,311	N/A
4/2/2017	52,598	7,281	N/A	15,677	N/A
12/31/2016	52,824	7,198	N/A	16,192	N/A
10/2/2016	53,243	6,270	N/A	15,049	N/A
7/3/2016	52,286	7,036	N/A	15,332	N/A
4/3/2016	50,992	7,615	N/A	15,816	N/A
12/31/2015	48,851	6,948	N/A	14,688	N/A
9/27/2015	47,922	8,366	N/A	15,188	N/A
6/28/2015	48,196	8,913	N/A	14,631	N/A
3/29/2015	49,116	9,200	N/A	14,628	N/A
12/31/2014	49,605	9,085	N/A	17,084	N/A
9/28/2014	50,045	10,461	N/A	17,209	N/A
6/29/2014	50,327	10,370	N/A	18,646	N/A
3/30/2014	50,527	10,994	N/A	18,316	N/A
12/31/2013	51,584	11,339	N/A	17,684	N/A
9/29/2013	51,917	10,185	N/A	16,908	N/A
6/30/2013	52,227	10,590	N/A	16,011	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PFE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: PFE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PFE is expected to become profitable in the next 3 years.

Revenue vs Market: PFE's revenue (2.6% per year) is forecast to grow slower than the US market (8.3% per year).

High Growth Revenue: PFE's revenue (2.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PFE's Return on Equity is forecast to be low in 3 years time (15.3%).

Pfizer Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Pfizer Inc. Provides Earnings Guidance for the Year 2024

Pfizer Inc. Re-Affirms Earnings Guidance for the Full-Year 2024

Pfizer Inc. Provides Earnings Guidance for the Full-Year 2024

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Recent updates

Pfizer Inc. Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong

Pfizer Announces Executive Changes

Pfizer: Ignore The Dead Cat Bounce

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc.'s (NYSE:PFE) Price Is Out Of Tune With Revenues

Pfizer Inc. Provides Earnings Guidance for the Year 2024

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?

Fourth quarter dividend of US$0.42 announced

U.S. FDA Approves Pfizer Inc.'s Beqvez (Fidanacogene Elaparvovec-Dzkt), A One-Time Gene Therapy for Adults with Hemophilia B

Pfizer Inc. Declares Second-Quarter 2024 Dividend, Payable on June 14, 2024

European Commission Approves Pfizer’s Emblaveo® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth

Pfizer: The Market Is Wrong

Pfizer Inc Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Pfizer Inc., Annual General Meeting, Apr 25, 2024

Pfizer Inc. to Report Q1, 2024 Results on May 01, 2024

Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns

European Commission Approves Pfizer Inc.’s PREVENAR 20 to Help Protect Infants and Children Against Pneumococcal Disease

Pfizer Announces Positive Overall Survival in Phase 3 Trial of Adcetris® Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Pfizer: A Value Trap, Not A Bargain

Insufficient new directors

New major risk - Financial position

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Pfizer: Turnaround Is Gaining Momentum

Is Pfizer (NYSE:PFE) A Risky Investment?

Pfizer Is A Great Investment Over The Next Decade; Buy

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Pfizer Inc. Re-Affirms Earnings Guidance for the Full-Year 2024

Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market

Full year 2023 earnings: EPS and revenues miss analyst expectations

Pfizer Inc. Provides Earnings Guidance for the Full-Year 2024

Consensus EPS estimates fall by 11%

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Consensus EPS estimates fall by 11%

Why I'm Avoiding 6%-Yielding Pfizer Stock

Upcoming dividend of US$0.42 per share at 6.0% yield

Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies